Circulation, Vol 66, 454-462, Copyright © 1982 by American Heart Association
HC Kou, JS Hung, YS Lee and D Wu
We performed electrophysiologic studies before and after oral
administration of disopyramide phosphate, 200 mg every 6 hours, in 20
patients with atrioventricular (AV) reentrant tachycardia using a
retrogradely conducting accessory pathway. Disopyramide markedly depressed
retrograde accessory pathway conduction by increasing the mean ventricular
paced cycle length that produced ventriculoatrial block (less than or equal
to 287 +/- 4 to greater than or equal to 392 +/- 22 msec, p less than
0.01); it also depressed antegrade normal pathway AV conduction by
increasing the atrial paced cycle length that produced AV block (287 +/- 9
to 328 +/- 7 msec, p less than 0.01). In 14 patients, tachycardia could not
be induced or sustained after disopyramide phosphate. In 13 patients, this
reflected depression of the retrograde limb with either absence of atrial
echoes (nine patients) or induction of nonsustained tachycardia that
terminated after the QRS complex (four patients), and in one, it reflected
depression of the antegrade limb with induction of a single atrial echo not
followed by a QRS response. In six patients, sustained tachycardia could
still be induced after disopyramide. Oral disopyramide phosphate is
effective in preventing induction of sustained AV reentrant tachycardia in
most patients. This effect is achieved by depression of the retrograde limb
of the reentrant circuit.
ARTICLES
Effects of oral disopyramide phosphate on induction and sustenance of atrioventricular reentrant tachycardia incorporating retrograde accessory pathway conduction
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1982 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |